Digitisation | August 11, 2021
Tesis Labs and Personal Genome Diagnostics tie-up to advance cancer treatment
The aim is to create new genomics solutions that could combat cancer and advance market access
The aim is to create new genomics solutions that could combat cancer and advance market access
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
Price band in the range of Rs 933 to Rs 954
In the interim, the statutory approvals obtained by the company under SEBI ICDR have lapsed in accordance with applicable law and are required to be re-obtained
Dr. Jindal reflects on bridging accessibility gaps between urban and rural regions, the ethical and emotional aspects of family building, and how initiatives like adoption facilitation centers align with his lifelong mission to help couples realize the dream of parenthood
The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million
New Phase III data on gefurulimab highlight potential as a self-administered treatment option; real-world evidence reinforces clinical benefits of Ultomiris and Soliris
Test delivers results in just 18 minutes, enabling faster laboratory workflows and patient management during outbreaks
Subscribe To Our Newsletter & Stay Updated
